{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=109",
    "query": {
      "intervention": "CTRL",
      "page": 109
    },
    "page_size": 10
  },
  "pagination": {
    "page": 109,
    "page_size": 10,
    "total_count": 26682,
    "total_pages": 2669,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=110&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=108&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T13:18:38.412Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07104825",
      "title": "Autonomic Neural Blockade in Bariatric Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bariatric Surgery Candidate",
        "Pain, Postoperative",
        "Nausea and Vomiting, Postoperative",
        "Opioid Use"
      ],
      "interventions": [
        {
          "name": "Intraoperative autonomic neural blockade (ANB)",
          "type": "PROCEDURE"
        },
        {
          "name": "Laparoscopic Standard of Care Abdominal Wall Block",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 200,
      "start_date": "2026-02-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104825"
    },
    {
      "nct_id": "NCT02496676",
      "title": "Magnesium Supplementation in People With XMEN Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "XMEN"
      ],
      "interventions": [
        {
          "name": "Magnesium L-threonate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Intravenous (IV) magnesium sulfate (MgSO4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2016-05-17",
      "completion_date": "2020-04-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02496676"
    },
    {
      "nct_id": "NCT02397889",
      "title": "Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Posttraumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-05-18",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397889"
    },
    {
      "nct_id": "NCT03392389",
      "title": "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Metapneumovirus and Human Parainfluenza Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1653",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 124,
      "start_date": "2017-12-04",
      "completion_date": "2019-07-29",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 3,
      "location_summary": "Omaha, Nebraska • Austin, Texas • Fort Worth, Texas",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03392389"
    },
    {
      "nct_id": "NCT04814368",
      "title": "A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LNA043",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to canakinumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-08-27",
      "completion_date": "2024-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 5,
      "location_summary": "La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04814368"
    },
    {
      "nct_id": "NCT01498874",
      "title": "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "gevokizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XOMA (US) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-12",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 19,
      "location_summary": "Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498874"
    },
    {
      "nct_id": "NCT06519097",
      "title": "Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasm of Pancreas",
        "IPMN, Pancreatic"
      ],
      "interventions": [
        {
          "name": "Vitamin E Delta Tocotrienol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-07-09",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Omaha, Nebraska",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06519097"
    },
    {
      "nct_id": "NCT01668797",
      "title": "Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 524,
      "start_date": "2012-10",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 14,
      "location_summary": "Anaheim, California • Cerritos, California • Garden Grove, California + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01668797"
    },
    {
      "nct_id": "NCT05295459",
      "title": "Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Sinusitis",
        "Chronic Rhinosinusitis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "LYR-210",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure control",
          "type": "DRUG"
        },
        {
          "name": "Background therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Lyra Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2022-05-13",
      "completion_date": "2025-04-02",
      "has_results": true,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 31,
      "location_summary": "Tucson, Arizona • Arcadia, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05295459"
    },
    {
      "nct_id": "NCT04272255",
      "title": "Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Motion Sickness"
      ],
      "interventions": [
        {
          "name": "scopolamine HBr",
          "type": "DRUG"
        },
        {
          "name": "Transdermal Scopolamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repurposed Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 300,
      "start_date": "2019-04-22",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-12T13:18:38.412Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04272255"
    }
  ]
}